Literature DB >> 16932387

Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis.

Danilo Fliser1, Jan T Kielstein.   

Abstract

Sustained low-efficiency dialysis (SLED) is an increasingly popular extracorporeal renal replacement therapy for patients with renal failure in the intensive care unit (ICU). Several centers across the world employ this 'hybrid' technique, which has advantages of both intermittent and continuous methods. The goal of these centers is to provide an easy-to-perform treatment with reduced solute clearances for prolonged periods. Many centers use standard, sophisticated dialysis equipment for SLED. An increasing number of hospitals in Europe and South America employ a single-pass batch dialysis system, the procedural simplicity of which makes it an ideal modality for SLED in the ICU. All systems offer the advantages of flexible timing of treatment and reduced costs; their ease of handling means that SLED is readily accepted by ICU staff. Prospective controlled studies have shown that SLED clears small solutes with an efficacy comparable to that of intermittent hemodialysis and continuous venovenous hemofiltration (even when the latter employs high rates of fluid substitution). Cardiovascular tolerability associated with SLED is similar to that associated with continuous renal replacement therapy, even in severely ill patients. Nocturnal dialysis -- a special form of SLED -- has all the advantages outlined above, with the added benefit of unrestricted physician access to the patient during the day, minimizing the interference of renal replacement therapy with other ICU activities.

Entities:  

Mesh:

Year:  2006        PMID: 16932387     DOI: 10.1038/ncpneph0060

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  26 in total

1.  Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment.

Authors:  Enrico Fiaccadori; Giuseppe Regolisti; Carola Cademartiri; Aderville Cabassi; Edoardo Picetti; Maria Barbagallo; Tiziano Gherli; Giuseppe Castellano; Santo Morabito; Umberto Maggiore
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

Review 2.  [Acute kidney injury in the perioperative setting].

Authors:  D Kindgen-Milles
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-05-22       Impact factor: 0.840

3.  Sustained low-efficiency extended dialysis (SLED) with single-pass batch system in critically-ill patients with acute kidney injury (AKI).

Authors:  Renato A Caires; Regina C R M Abdulkader; Verônica T Costa E Silva; Gillene S Ferreira; Emmanuel A Burdmann; Luis Yu; Etienne Macedo
Journal:  J Nephrol       Date:  2015-08-23       Impact factor: 3.902

Review 4.  Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.

Authors:  Antonio D'Avolio; Debora Pensi; Lorena Baietto; Giovanni Pacini; Giovanni Di Perri; Francesco Giuseppe De Rosa
Journal:  Drugs       Date:  2016-08       Impact factor: 9.546

Review 5.  Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group "Renal Replacement Therapies in Critically Ill Patients" of the Italian Society of Nephrology.

Authors:  Enrico Fiaccadori; Valentina Pistolesi; Filippo Mariano; Elena Mancini; Giorgio Canepari; Paola Inguaggiato; Marco Pozzato; Santo Morabito
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

6.  Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.

Authors:  Verena Hafner; David Czock; Jürgen Burhenne; Klaus-Dieter Riedel; Jürgen Bommer; Gerd Mikus; Christoph Machleidt; Thomas Weinreich; Walter E Haefeli
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

7.  Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.

Authors:  Johan M Lorenzen; Michael Broll; Volkhard Kaever; Heike Burhenne; Carsten Hafer; Christian Clajus; Wolfgang Knitsch; Olaf Burkhardt; Jan T Kielstein
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

Review 8.  Prolonged intermittent renal replacement therapy in children.

Authors:  Rajiv Sinha; Sidharth Kumar Sethi; Timothy Bunchman; Valentine Lobo; Rupesh Raina
Journal:  Pediatr Nephrol       Date:  2017-07-18       Impact factor: 3.714

9.  [Acute renal failure. Extracorporeal therapy].

Authors:  J T Kielstein; D Fliser
Journal:  Internist (Berl)       Date:  2007-08       Impact factor: 0.743

Review 10.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.